Int J Mol Med 14: [Related article:] 414–424, 2018; DOI:
10.3892/ijmm.2018.3590
An interested reader drew to our attention that the
above study appeared to contain a high level of overlap with an
article by the same authors published in the journal Drug
Design, Development and Therapy [Kadivar A, Kamalidehghan B,
Akbari Javar H, Karimi B, Sedghi R and Noordin MI:
Antiproliferation effect of imatinib mesylate on MCF7, T-47D
tumorigenic and MCF 10A nontumorigenic breast cell lines via
PDGFR-β, PDGF-BB, c-Kit and SCF genes. Drug Des Devel Ther 11:
469-481, 2017]. Following an internal investigation and also in
liaison with the authors, it was established that, although the
studies were conducted along broadly similar lines, the papers
contained entirely different data involving two different subsets
of cell lines; the submission to Drug Des Devel Ther aimed
to explore the effects of imatinib mesylate on three different
groups, with each group being represented by a cell line, whereas
the submission to Int J Mol Med explored the effectiveness
of imatinib mesylate in breast cancer cell lines. In spite of this,
considering the relatedness of the articles and the fact that the
paper to Drug Des Devel Ther was submitted first and
published while the Int J Mol Med paper was passing through
the peer-review process, the authors concede that they should have
properly referenced their paper submitted to Drug Des Devel
Ther in the Int J Mol Med paper. Note that the
publishers of Drug Des Devel Ther, with whom we were
liaising, agreed with the decision to issue a Corrigendum for this
paper that acknowledges the article published in Drug Des Devel
Ther.
The authors regret their failure to acknowledge the
related paper in this instance, and apologize to the readership for
this oversight.
